Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab + Ibrutinib in B-Cell Malignancies
NCT02013128Phase 2Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), sponsored by TG Therapeutics, Inc.. Started Jan 2014; status: completed.
02
Drugs
ublituximab
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02013128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02013128.